Lisata Therapeutics, Inc. financial data

Symbol
LSTA on Nasdaq
Industry
Pharmaceutical Preparations
Location
110 Allen Road, Second Floor, Basking Ridge, NJ
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Caladrius Biosciences, Inc. (to 9/15/2022), CALADRIUS BIOSCIENCES, INC. (to 9/15/2022), NeoStem, Inc. (to 6/5/2015), PHASE III MEDICAL INC/DE (to 9/1/2006), CORNICHE GROUP INC /DE (to 8/14/2003)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 933 % -24.2%
Debt-to-equity 12.2 % +32.4%
Return On Equity -46.5 % +44.4%
Return On Assets -41.4 % +45.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.32M shares +2.18%
Common Stock, Shares, Outstanding 8.32M shares +2.32%
Entity Public Float 25.1M USD -19.8%
Common Stock, Value, Issued 8K USD 0%
Weighted Average Number of Shares Outstanding, Basic 8.31M shares +3.58%
Weighted Average Number of Shares Outstanding, Diluted 8.31M shares +3.58%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 14.8M USD -3.58%
Operating Income (Loss) -24.1M USD +58.4%
Nonoperating Income (Expense) 2.24M USD +8.77%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -21.9M USD +60.9%
Income Tax Expense (Benefit) -1.6M USD -4.44%
Net Income (Loss) Attributable to Parent -21.1M USD +60.7%
Earnings Per Share, Basic -2.57 USD/shares +71.6%
Earnings Per Share, Diluted -2.57 USD/shares +71.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28.3M USD +19.4%
Cash, Cash Equivalents, and Short-term Investments 33.8M USD -36.7%
Assets, Current 42M USD -31.7%
Property, Plant and Equipment, Net 119K USD -48.9%
Operating Lease, Right-of-Use Asset 225K USD -41.9%
Intangible Assets, Net (Excluding Goodwill) 400K USD 0%
Other Assets, Noncurrent 246K USD -40%
Assets 42.6M USD -31.7%
Accounts Payable, Current 728K USD -6.07%
Employee-related Liabilities, Current 1.7M USD -20%
Accrued Liabilities, Current 3.73M USD +4.13%
Liabilities, Current 4.46M USD +2.32%
Operating Lease, Liability, Noncurrent 47K USD -78.9%
Other Liabilities, Noncurrent 119K USD -59.7%
Liabilities 4.58M USD -1.61%
Accumulated Other Comprehensive Income (Loss), Net of Tax -77K USD -54%
Retained Earnings (Accumulated Deficit) -539M USD -4.07%
Stockholders' Equity Attributable to Parent 38.2M USD -34%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 38M USD -34.2%
Liabilities and Equity 42.6M USD -31.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.03M USD +14.3%
Net Cash Provided by (Used in) Financing Activities -142K USD -67.1%
Net Cash Provided by (Used in) Investing Activities 6.44M USD +50.1%
Common Stock, Shares Authorized 500M shares +1400%
Common Stock, Shares, Issued 8.32M shares +2.32%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -788K USD +80.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 28.3M USD +19.4%
Deferred Tax Assets, Valuation Allowance 23.5M USD +3.48%
Deferred Tax Assets, Gross 23.6M USD +2.79%
Operating Lease, Liability 223K USD -41.8%
Depreciation 29K USD -3.33%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.1M USD +60.6%
Lessee, Operating Lease, Liability, to be Paid 238K USD -44.4%
Property, Plant and Equipment, Gross 661K USD 0%
Operating Lease, Liability, Current 176K USD +10%
Lessee, Operating Lease, Liability, to be Paid, Year Two 143K USD -24.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 143K USD -24.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 15K USD -66.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 143K USD -24.7%
Deferred Tax Assets, Operating Loss Carryforwards 12.7M USD -3.02%
Preferred Stock, Shares Issued 10K shares 0%
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 344K USD 0%
Additional Paid in Capital 578M USD +0.24%
Preferred Stock, Shares Outstanding 10K shares 0%
Amortization of Intangible Assets 20K USD 0%
Share-based Payment Arrangement, Expense 1.47M USD -46.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%